Shots:
- Amberstone Biosciences has entered into a collaboration & license agreement with Henlius Biotech to advance conditionally activated T-cell engagers for the treatment of solid tumors
- As per the deal, Amberstone will use its T-MATE platform to generate preclinical candidates against ~2 Henlius-selected targets, while Henlius will lead subsequent research, development, manufacturing & global commercialization
- Amberstone will receive an upfront payment & research funding, plus ~$440M in potential development, regulatory, & sales milestones for each target, with tiered royalties on net sales
Ref: PRnewswire | Image: Amberstone & Henlius | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
